Company Profile
Fulcrum Therapeutics Stock Price, News & Analysis
- Ticker:
- FULC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.77 USD (0.00%)
Close
Last updated: August 6, 2026
209M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, FULC was little changed and closed at $3.77. No new same-company headline was identified in the current news window.
Company overview
Gene-Expression Drug Discovery
Fulcrum Therapeutics develops small molecules that modulate gene expression in genetically defined diseases. Its current focus is rare hematologic disease and the use of oral therapy to alter red-blood-cell biology.
Pociredir
Pociredir is an oral inhibitor of embryonic ectoderm development designed to increase fetal hemoglobin in sickle cell disease. Higher fetal hemoglobin can reduce hemoglobin polymerization, hemolysis, anemia and vaso-occlusive complications.
Clinical Development Strategy
The PIONEER program demonstrated rapid fetal-hemoglobin induction and encouraging changes in disease markers. Fulcrum has also started a long-term study to assess durability and safety in previously treated participants while preparing a potentially registration-enabling trial.
Future catalysts
Update on the next pociredir trial design expected in the second quarter of 2026 following FDA meeting minutes.
Initiation of a potential registration-enabling pociredir trial planned in the second half of 2026, pending FDA feedback.
Recent news
- 01
- 02
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Fulcrum Therapeutics
- 03
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Source: Fulcrum Therapeutics
- 04
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Source: Fulcrum Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fulcrum Therapeutics (FULC)?
Fulcrum Therapeutics (FULC) most recently closed at 3.77 USD, a 0.00% move versus the previous session.
What is the market cap of Fulcrum Therapeutics (FULC)?
Fulcrum Therapeutics currently has a market capitalization of 209M USD on BioPharmSignal.
What does Fulcrum Therapeutics do?
Gene-Expression Drug Discovery Fulcrum Therapeutics develops small molecules that modulate gene expression in genetically defined diseases. Its current focus is rare hematologic disease and the use of oral therapy to alter red-blood-cell biology. Pociredir Pociredir is an oral inhibitor of embryonic ectoderm development designed to increase fetal hemoglobin...
On which exchange is FULC stock listed?
Fulcrum Therapeutics (FULC) is associated with NASDAQ, United States, Biopharma.
What is Gene-Expression?
Gene-Expression Drug Discovery Fulcrum Therapeutics develops small molecules that modulate gene expression in genetically defined diseases.
Which conditions is Fulcrum Therapeutics targeting with Gene-Expression?
Fulcrum Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Fulcrum Therapeutics describe recent progress with Gene-Expression?
Update on the next pociredir trial design expected in the second quarter of 2026 following FDA meeting minutes. Initiation of a potential registration-enabling pociredir trial planned in the second half of 2026, pending FDA feedback.
What is Drug?
Gene-Expression Drug Discovery Fulcrum Therapeutics develops small molecules that modulate gene expression in genetically defined diseases.